

# High Cost Claimants among Active Employees, Early Retirees and Their Dependents



November 2019

# Key findings

- While high cost claimants<sup>1</sup> (“HCC”) enrolled in the GHIP during FY19 spanned all age ranges, member types (employee, spouse, etc.) and status groups (Active, non-Medicare Pensioner, etc.), these claimants were most often:
  - Aged 50-59 years old (35% of all HCC)
  - Spouses (61% of all HCC)
- Over the last 4 fiscal years (FY16 – FY19):
  - Prevalence of HCCs increased (from 6.1 to 7.4 HCCs per 1,000 members)
  - Total cost associated with HCCs increased (from 22% to 25% of net payments attributable to HCCs)
  - Cost per HCC increased (from \$108 to \$135 net paid per member per month (PMPM))
  - Cost per HCC has been trending higher and with more variability year to year compared to non-HCC cost increases, particularly from FY17 to FY18 (15.5% increase in net paid PMPM for HCCs vs. minimal increase for non-HCCs)

<sup>1</sup> HCCs are patients with \$100,000 or more of incurred claims during the reporting period.

## Key findings

- Of the 776 HCCs in FY19, 283 (36.4%) incurred costs of \$100,000 or more in multiple fiscal years and 43 (5.5%) met this threshold in all of the past four fiscal years (FY16 – FY19)
  - Top clinical conditions driving multi-year HCCs include conditions associated with newborns, cancer (breast, leukemia, lung) and coronary artery disease
  - One of the top 10 most expensive HCCs in FY19 has been a HCC for all four years and has been continuously enrolled in the First State Basic plan as a non-Medicare pensioner; this claimant is currently engaged with a Highmark CCMU nurse care manager
- Top clinical conditions driving total HCC costs in FY19 are similar to those of multi-year HCCs
- Skin burns, congenital respiratory disorders, and mental health treatment associated with schizophrenia have the highest costs per patient, but are not necessarily the top conditions driving overall costs (relatively few number of each of these types of claimants)

## Key findings

- While not possible to prevent all HCCs, a multi-pronged effort can be effective in mitigating HCC cost and potentially preventing some members from becoming HCCs; this effort includes:
  - Member education to promote health engagement
  - Age/gender-appropriate preventive screenings
  - Effective management of chronic conditions (i.e., primary care)
  - Supporting members in navigating the health care system
  - Care management programs that support members with the most acute health care needs
- Opportunity to evaluate the effectiveness of third party administrators (TPA) in delivering programs that support the State across the components noted above
  - Completion of this evaluation within the next 2-3 months would allow for incorporation of any findings into the TPA contract renewal process for FY21

# Overview


## Objectives:

- Examine high level cost and utilization for High Cost Claimants (HCCs).
- Provide a snapshot of what portion of the HCC population continues to incur high costs over time.
- Provide a demographic overview of HCCs.
- Understand the top clinical conditions and medical episodes experienced by high cost claimants.
- Identify the highest cost cases and provide a profile to understand variation in contributing conditions.

## Analytic Parameters



- Active Employees & Early Retirees, Their Spouses and Dependents
- Age Limited to 64 and Younger (at start of FY19) & Medicfill excluded
- Fiscal Years 2016-2019
- HCCs are patients with \$100,000 or more of incurred claims during the reporting period.

# FY19 High Cost Claimants (HCCs) Demographics (n=776)



## Movement of HCCs between Employee Status Groups during FY19:

- 51 HCCs moved directly from Active Employees to Early Retirees;
- 14 HCCs moved directly from Early Retirees to Medicare
- 7 HCCs moved from Active Employees to either Cobra, Medicare Early Retirees in assorted combinations.
- 60 HCC patients were no longer enrolled in the final month of eligibility of FY19.






\*Status groups are not mutually exclusive

# High Cost Claimants (HCCs) Trends

Over the last 4 fiscal years (2016-2019):

- the rate of HCCs per 1000 members increased from 6.1 to 7.4
- the percent of net payments attributable to HCCs increased from 22% to 25%
- net payments per member per month (PMPM) increased for High Cost Claimants from \$108 to \$135; and
- the net payment PMPM trend for HCCs exceeded the trend for non-HCCs in each of the observed periods, particularly from FY17 to FY18 (15.5% trend for HCCs vs a flat trend for non-HCCs).



## High Cost Claimants & Top 50 Highest Cost Claimants (HCCs) Net Payment Range for FY19 and Four Year Experience

	All High Cost Claimants	Top 50 Highest Cost Claimants
Patients in FY19	776	50
Range of Net Payments, FY19	\$100,320 - \$1,869,030	\$409,128 - \$1,869,030
HCCs Enrolling in Medicare	18 (2.3%)	----
- Only HCCs in FY19	10	
- HCCs in FY18-FY19	5	
- HCC in Multiple Prior Years	3	
HCCs in FY19 Only	475 (61.2%)	23 (46%)
HCCs in FY18 through FY19	142 (18.3%)	11 (22%)
HCCs in FY17 through FY19	55 (7.1%)	5 (10%)
HCCs in FY16 through FY19	43 (5.5%)	8 (16%)
HCCs in other Multiple Year Combinations	43 (5.5%)	3 (6%)

Of the 776 HCCs in FY19, 283 (36.4%) incurred costs of \$100,000 or more in multiple fiscal years and 43 (5.5%) met this threshold in all four fiscal years.



# High Cost Claimants

## Top 5 Episode Summary Groups by Total FY19 Net Payments – All Plans

Episode Summary Group	HCC Patients		Net Payments for HCCs			PMPM		
	% of HCCs		% of Total Paid Claims					
	FY18	FY19	FY18	FY19	Per Patient Trend	FY18	FY19	PMPM Trend
Newborns	30	34	\$4.5 M	\$7.7 M	51%	\$4	\$7	69.8%
	3.9%	4.4%	0.8%	1.3%				
Breast Cancer	53	66	\$6.7 M	\$7.6 M	-9%	\$6	\$7	12.6%
	6.9%	8.5%	1.1%	1.2%				
Leukemia	50	36	\$6.0 M	\$5.2 M	22%	\$5	\$5	<b>-12.9%</b>
	6.5%	4.6%	1.0%	0.9%				
Coronary Artery Disease	91	95	\$4.5 M	\$5.2 M	11%	\$4	\$5	11.4%
	11.8%	12.2%	0.8%	0.9%				
Lung Cancer	34	42	\$4.9 M	\$5.1 M	-14%	\$4	\$4	5.0%
	4.4%	5.4%	0.7%	0.8%				

# High Cost Claimants

## Top 5 Episode Summary Groups by Total FY19 Net Payments – Aetna CDH

Episode Summary Group	FY17			FY18			FY19			PMPM Trend	
	Patients	Net Payments	PMPM	Patients	Net Payments	PMPM	Patients	Net Payments	PMPM	FY17-18	FY18-19
Renal Function Failure	---	---	---	2	\$162.9 K	\$6	3	\$570.2 K	\$9	---	52.7%
Hypertension, Essential	---	---	---	4	\$34.0 K	\$1	9	\$494.0 K	\$8	---	533.3%
Coronary Artery Disease	---	---	---	4	\$233.8 K	\$9	5	\$351.7 K	\$6	---	-34.3%
Cancer - Breast	1	\$97.0 K	\$8	2	\$240.1 K	\$9	3	\$331.4 K	\$5	10.8%	-39.8%
Cardiovasc Disord, Congenital	---	---	---	---	---	---	1	\$332.8 K	\$5	---	---

# High Cost Claimants

## Top 5 Episode Summary Groups by Total FY19 Net Payments – Aetna HMO

Episode Summary Group	FY17			FY18			FY19			PMPM Trend	
	Patients	Net Payments	PMPM	Patients	Net Payments	PMPM	Patients	Net Payments	PMPM	FY17-18	FY18-19
Cancer - Lung	2	\$269.7 K	\$3	10	\$1.8 M	\$6	15	\$2.2 M	\$7	66.1%	32.1%
Coronary Artery Disease	3	\$236.0 K	\$3	21	\$1.1 M	\$3	33	\$2.0 M	\$7	16.4%	101.5%
Chemotherapy Encounters	2	\$48.3 K	\$1	4	\$877.1 K	\$3	7	\$1.9 M	\$6	347.8%	138.9%
Skin Burns	---	---	\$0	---	---	---	3	\$1.8 M	\$6	---	---
Multiple Sclerosis	1	\$149.8 K	\$2	11	\$1.7 M	\$5	10	\$1.7 M	\$6	179.7%	10.2%

# High Cost Claimants

## Top 5 Episode Summary Groups by Total FY19 Net Payments – Highmark FSB

Episode Summary Group	FY17			FY18			FY19			PMPM Trend	
	Patients	Net Payments	PMPM	Patients	Net Payments	PMPM	Patients	Net Payments	PMPM	FY17-18	FY18-19
Cardiomyopathy	1	\$39.2 K	\$2	2	\$54.8 K	\$1	2	\$671.7 K	\$11	-35.5%	1017.9%
Newborns, w/wo Complication	2	\$712.3 K	\$28	2	\$199.2 K	\$4	1	\$603.8 K	\$10	-87.1%	176.2%
Cancer - Leukemia	---	---	---	2	\$520.3 K	\$9	2	\$409.6 K	\$7	---	-28.2%
Condition Rel to Tx - Med/Surg	3	\$35.2 K	\$1	4	\$31.4 K	\$1	5	\$240.7 K	\$4	-58.8%	598.0%
Cancer - Colon	---	---	---	4	\$665.0 K	\$12	2	\$212.6 K	\$4	---	-70.9%

# High Cost Claimants

## Top 5 Episode Summary Groups by Total FY19 Net Payments – Highmark PPO

Episode Summary Group	FY17			FY18			FY19			PMPM Trend	
	Patients	Net Payments	PMPM	Patients	Net Payments	PMPM	Patients	Net Payments	PMPM	FY17-18	FY18-19
Newborns, w/wo Complication	15	\$1.9 M	\$3	21	\$3.4 M	\$5	26	\$6.8 M	\$9	54.0%	90.7%
Cancer - Breast	28	\$3.7 M	\$6	43	\$5.3 M	\$8	49	\$6.2 M	\$8	21.4%	11.1%
Renal Function Failure	51	\$3.6 M	\$6	61	\$3.7 M	\$5	53	\$3.9 M	\$5	-12.2%	1.1%
Crohns Disease	9	\$1.1 M	\$2	23	\$2.5 M	\$4	24	\$3.4 M	\$5	93.6%	31.8%
Multiple Sclerosis	12	\$1.6 M	\$3	29	\$4.6 M	\$7	26	\$3.1 M	\$4	153.4%	-36.9%

# High Cost Claimants – Patients and Net Payments by Service Category

## FY18 and FY19

Service Category	HCC Patients		Net Payments for HCCs		PMPM		
	% of HCCs		% of Total Paid Claims				
	FY18	FY19	FY18	FY19	FY18	FY19	Trend
Facility Inpatient	465	445	\$56.9 M	\$56.3 M	\$50	\$49	-1.9%
	60.5%	57.3%	9.6%	9.1%			
Facility Outpatient	694	691	\$42.5 M	\$43.7 M	\$37	\$38	2.0%
	90.2%	89.0%	7.2%	7.1%			
Laboratory Outpatient	716	731	\$1.3 M	\$ 1.2 M	\$1	\$1	-6.4%
	93.1%	94.2%	0.2%	0.2%			
MHSA	222	225	\$ 1.8 M	\$ 2.6 M	\$2	\$2	42.8%
	28.9%	29.0%	0.3%	0.4%			
Other Professional Services	753	749	\$10.6 M	\$11.2 M	\$9	\$10	5.5%
	97.9%	96.5%	1.8%	1.8%			
Physician Inpatient	496	473	\$5.2 M	\$5.4 M	\$5	\$5	2.2%
	64.5%	61.0%	0.9%	0.9%			
Physician Outpatient	764	769	\$2.7 M	\$2.9 M	\$2	\$2	5.4%
	99.3%	99.1%	0.5%	0.5%			
Prescription Drugs	752	753	\$19.8 M	\$23. 3 M	\$17	\$21	21.7%
	97.8%	97.0%	3.4%	3.9%			
Radiology Outpatient	641	640	\$8.3 M	\$8.6 M	\$7	\$7	2.9%
	83.4%	82.5%	1.4%	1.4%			
<b>Totals</b>	<b>769</b>	<b>776</b>	<b>\$149 M</b>	<b>\$156 M</b>	<b>\$130</b>	<b>\$135</b>	<b>3.9%</b>

# High Cost Claimants – Patients and Net Payments by Medical Benefit Specialty Drugs (Medical Benefit) FY18 and FY19

Service Category	HCC Patients		Net Payments for HCCs		PMPM		
	% of HCCs		% of Total Paid Claims				
	FY18	FY19	FY18	FY19	FY18	FY19	Trend
Outpatient	332	337	\$27.4 M	\$27.9 M	\$24	\$24	1.2%
Inpatient	174	177	\$1.6 M	\$1.9 M	\$2	\$2	-0.7%

# Patient Stratification by Net Payment Range

## FY19

Range	Patients	Total Net Payments	% Medical	% Rx	Cumulative Percent of Patients	Cumulative Percent of Total Net Payments
\$0.00	1,376	---	---	---	100.0%	100.0%
\$0.01 - \$4,999.99	74,399	\$95,280,568	77.9%	22.1%	98.6%	100.0%
<b>\$5,000.00 - \$9,999.99</b>	<b>9,156</b>	<b>\$63,861,906</b>	<b>73.5%</b>	<b>26.5%</b>	<b>22.1%</b>	<b>84.6%</b>
\$10,000.00 - \$14,999.99	3,780	\$45,705,475	73.6%	26.4%	12.7%	74.2%
\$15,000.00 - \$19,999.99	2,230	\$38,261,429	77.5%	22.5%	8.8%	66.8%
\$20,000.00 - \$29,999.99	2,363	\$57,002,697	79.0%	21.0%	6.5%	60.6%
\$30,000.00 - \$39,999.99	1,133	\$38,846,333	78.3%	21.7%	4.1%	51.3%
\$40,000.00 - \$49,999.99	719	\$31,903,735	77.1%	22.9%	2.9%	45.0%
\$50,000.00 - \$99,999.99	1,316	\$89,780,749	71.2%	28.8%	2.2%	39.9%
<b>\$100,000.00 - \$199,999.99</b>	<b>533</b>	<b>\$71,845,394</b>	<b>79.2%</b>	<b>20.8%</b>	<b>0.8%</b>	<b>25.3%</b>
<b>over \$199,999.99</b>	<b>243</b>	<b>\$84,311,332</b>	<b>88.9%</b>	<b>11.1%</b>	<b>0.2%</b>	<b>13.7%</b>
<b>Totals</b>	<b>97,251</b>	<b>\$616,796,275</b>	<b>77.9%</b>	<b>22.1%</b>		

- About 22% of the patient population accounted for about 85% of total net payments.
- Less than 1% of the population were High Cost Claimants (HCCs). HCCs accounted for just over 25% of total net payments.



# High Cost Claimants by Plan FY19

Plan	HCCs <i>(Top 50 HCCs)</i>	% HCCs (HCC/Patients)	Net Payments for HCCs	Total Plan Net Payments	% Payments for HCCs	Avg. Cost per HCC
<b>CDH Gold</b>	28 (2)	0.5%	\$5,639,760	\$25,104,947	22.5%	\$201,420
<b>HMO</b>	183 (12)	0.8%	\$36,907,888	\$138,848,522	26.6%	\$201,682
<b>First State Basic</b>	21 (2)	0.4%	\$4,650,464	\$21,722,506	21.4%	\$221,451
<b>PPO</b>	544 (34)	0.9%	\$108,723,385	\$429,634,199	25.3%	\$199,859

## Top Clinical Conditions by Total Net Payments FY19

	Top 50 HCCs			All HCCs		
	Net Payments	Patients	Net Pay per Patient	Net Payments	Patients	Net Pay per Patient
Chemotherapy Encounters	\$5,405,077	16	\$337,817	\$14,920,910	148	\$100,817
Coronary Artery Disease	\$1,341,621	11	\$121,966	\$5,953,347	113	\$52,684
Newborns, w/wo Complication	\$2,411,260	8	\$301,408	\$5,717,234	35	\$163,350
Renal Function Failure	\$1,026,750	11	\$93,341	\$5,235,068	120	\$43,626
Spinal/Back Disord, Low Back	\$20,326	5	\$4,065	\$5,054,692	202	\$25,023
Respiratory Disord, NEC	\$2,793,870	32	\$87,308	\$4,469,038	345	\$12,954
Condition Rel to Tx - Med/Surg	\$1,224,542	20	\$61,227	\$3,758,463	184	\$20,426
Cancer - Breast	\$212,288	3	\$70,763	\$3,654,070	70	\$52,201
Radiation Therapy Encounters	\$76,653	3	\$25,551	\$3,445,579	57	\$60,449
Hypertension, Essential	\$1,714,137	22	\$77,915	\$3,299,269	284	\$11,617

## Top Clinical Conditions by Net Payment per Patient FY19

	Top 50 HCCs			All HCCs		
	Net Payments	Patients	Net Pay per Patient	Net Payments	Patients	Net Pay per Patient
Skin Burns	\$1,773,409	1	\$1,773,409	\$1,775,631.49	5	\$355,126
Newborns, w/wo Complication	\$2,411,260	8	\$301,408	\$5,717,234	35	\$163,350
Foreign Body - Gastroint	\$318,775	1	\$318,775	\$428,328.64	3	\$142,776
Respiratory Disord, Congenital	\$326,650	1	\$326,650	\$513,046.81	4	\$128,262
Anomalies - Genitourinary	\$341,797	2	\$170,899	\$342,735.56	3	\$114,245
Chemotherapy Encounters	\$5,405,077	16	\$337,817	\$14,920,910	148	\$100,817
Mental Hlth - Schizophrenia	\$118,425	2	\$59,213	\$398,741.51	4	\$99,685
Hematologic Disord, Congenital	---	---	---	\$517,681.72	6	\$86,280
Alpha 1-Antitrypsin Deficiency	\$187,430	1	\$187,430	\$329,608.76	4	\$82,402
Multiple Sclerosis	---	---	---	\$2,954,304.62	38	\$77,745

## Top Clinical Conditions by Total Patients FY19

	Top 50 HCCs			All HCCs		
	Net Payments	Patients	Net Pay per Patient	Net Payments	Patients	Net Pay per Patient
Signs/Symptoms/Oth Cond, NEC	\$331,552	43	\$7,711	\$2,675,986	616	\$4,344
Prevent/Admin Hlth Encounters	\$47,585	36	\$1,322	\$786,033	593	\$1,326
Respiratory Disord, NEC	\$2,793,870	32	\$87,308	\$4,469,038	345	\$12,954
Arthropathies/Joint Disord NEC	\$30,486	21	\$1,452	\$1,278,495	333	\$3,839
Gastroint Disord, NEC	\$61,338	26	\$2,359	\$1,731,188	286	\$6,053
Hypertension, Essential	\$1,714,137	22	\$77,915	\$3,299,269	284	\$11,617
Cardiovasc Disord, NEC	\$186,436	25	\$7,457	\$1,705,858	251	\$6,796
Infec/Inflam - Skin/Subcu Tiss	\$21,537	15	\$1,436	\$576,632	220	\$2,621
Diabetes	\$490,934	13	\$37,764	\$1,678,351	203	\$8,268
Spinal/Back Disord, Low Back	\$20,326	5	\$4,065	\$5,054,692	202	\$25,023

## Top Episode Groups by Net Payments FY19

	Top 50 HCCs			All HCCs		
	Net Payments	Patients	Net Pay per Patient	Net Payments	Patients	Net Pay per Patient
Cancer - Breast	\$468,170	3	\$156,057	\$7,925,630.13	68	\$116,553
Newborns	\$4,548,623	8	\$568,578	\$7,771,094.20	34	\$228,562
Cancer - Leukemia	\$752,201	3	\$250,734	\$5,591,032.27	39	\$143,360
Coronary Artery Disease	\$122,791	6	\$20,465	\$5,293,407.99	97	\$54,571
Renal Function Failure	\$1,140,821	7	\$162,974	\$5,238,338.27	81	\$64,671
Cancer - Lung	\$1,224,288	5	\$244,858	\$5,152,609.19	43	\$119,828
Multiple Sclerosis				\$5,029,408.26	38	\$132,353
Chemotherapy Encounters	\$1,493,655	7	\$213,379	\$4,543,899.88	40	\$113,597
Crohns Disease	\$457,984	1	\$457,984	\$4,320,980.93	31	\$139,386
Diabetes	\$672,728	10	\$67,273	\$3,847,566.64	166	\$23,178

## Top Episode Groups by Net Payment Per Patient FY19

	Top 50 HCCs			All HCCs		
	Net Payments	Patients	Net Pay per Patient	Net Payments	Patients	Net Pay per Patient
Skin Burns	\$1,784,136	1	\$1,784,136	\$1,785,800	5	\$357,160
Respiratory Disord, Congenital	\$696,646	1	\$696,646	\$1,403,172	4	\$350,793
Mental Hlth - Schizophrenia	\$560,898	1	\$560,898	\$838,295	3	\$279,432
Foreign Body - Gastroint	\$327,290	1	\$327,290	\$502,025	2	\$251,013
Newborns	\$4,548,623	8	\$568,578	\$7,771,094	34	\$228,562
Alpha 1-Antitrypsin Deficiency	\$391,993	1	\$391,993	\$533,171	3	\$177,724
Cancer - Lymphoma	\$1,216,527	5	\$243,305	\$2,879,328	20	\$143,966
Cancer - Leukemia	\$752,201	3	\$250,734	\$5,591,032	39	\$143,360
Anomalies - Genitourinary	\$417,580	2	\$208,790	\$418,594	3	\$139,531
Crohns Disease	\$457,984	1	\$457,984	\$4,320,981	31	\$139,386

## Top Episode Groups by Total Patients FY19

	Top 50 HCCs			All HCCs		
	Net Payments	Patients	Net Pay per Patient	Net Payments	Patients	Net Pay per Patient
Prevent/Admin Hlth Encounters	\$28,549	27	\$1,057	\$852,599.91	488	\$1,747
Hypertension, Essential	\$441,039	15	\$29,403	\$3,107,757.69	216	\$14,388
Infec/Inflam - Skin/Subcu Tiss	\$20,224	13	\$1,556	\$912,575.15	190	\$4,803
Arthropathies/Joint Disord NEC	\$40,103	10	\$4,010	\$815,278.08	175	\$4,659
Diabetes	\$672,728	10	\$67,273	\$3,847,566.64	166	\$23,178
Infections - ENT Ex Otitis Med	\$781,830	7	\$111,690	\$973,516.12	166	\$5,865
Spinal/Back Disord, Low Back	\$20,617	5	\$4,123	\$3,830,225.04	159	\$24,089
Infections - Respiratory, NEC	\$84,621	9	\$9,402	\$716,544.21	121	\$5,922
Spinal/Back Disord, Ex Low	\$17,370	6	\$2,895	\$1,552,879.29	118	\$13,160
Osteoarthritis				\$2,537,264.46	114	\$22,257

## Current Rolling Year High Cost Claimants & Top 50 Highest Cost Claimants (HCCs) by Plan, Gender and Age Group<sup>1</sup>

Highmark Plans	Gender	Age Group	Top 50 HCCs (% of Cohort)	All HCCs (% of Cohort)
First State Basic	Female	0-1	1 (2.0%)	1 (0.1%)
		2-17	---	1 (0.1%)
		18-39	---	3 (0.4%)
		40-64	---	6 (0.8%)
	Male	0-1	---	---
		2-17	---	2 (0.3%)
		18-39	---	1 (0.1%)
		40-64	1 (2.0%)	7 (0.9%)
PPO	Female	0-1	3 (6.0%)	15 (1.9%)
		2-17	1 (2.0%)	22 (2.8%)
		18-39	3 (6.0%)	51 (6.6%)
		40-64	11 (22.0%)	234 (30.2%)
	Male	0-1	4 (8.0%)	13 (1.7%)
		2-17	4 (8.0%)	18 (2.3%)
		18-39	2 (4.0%)	28 (3.6%)
		40-64	7 (14.0%)	178 (22.9%)



## Current Rolling Year High Cost Claimants & Top 50 Highest Cost Claimants (HCCs) by Plan, Gender and Age Group

Aetna Plans	Gender	Age Group	Top 50 HCCs (% of Cohort)	All HCCs(% of Cohort)
CDH Gold	Female	0-1	---	1 (0.1%)
		2-17	---	1 (0.1%)
		18-39	---	5 (0.6%)
		40-64	1 (2.0%)	6 (0.8%)
	Male	0-1	---	1 (0.1%)
		2-17	---	---
		18-39	---	---
		40-64	1 (2.0%)	15 (1.9%)
HMO	Female	0-1	---	1 (0.1%)
		2-17	---	5 (0.6%)
		18-39	1 (2.0%)	15 (1.9%)
		40-64	5 (10%)	77 (9.9%)
	Male	0-1	---	5 (0.6%)
		2-17	1 (2.0%)	4 (0.5%)
		18-39	---	8 (1.0%)
		40-64	5 (10%)	71 (9.1%)

# Top 10 Highest Cost Claimants - Summary

## FY19

- The ten highest cost patients incurred \$11.9 million in total plan payments during the current rolling year.
- Over 99% of these costs were payments incurred on the medical benefit.
- Of the ten highest cost patients there were:
  - 44 hospital admissions;
  - 1,219 days in the hospital;
  - 20 emergency room visits;
  - 1,699 patient visits (unique date and provider);
  - 5 dependents, of which 4 patients were newborns and/or infants with complications;
  - 7 members in the PPO plan;
  - 7 that were HCCs in FY19, 2 that were HCCs in FY18 and FY19, and 1 that was a HCC in all four years.

## Top 10 Highest Cost Claimants Profile FY19

Status Relationship	Gender Age	Plan	Net Payments Net Medical Net Rx	Admits Days	Visits ER Visits	Episode Summary Group (Highest Cost) Top 3 Dx (Highest Cost)
Early Retiree ----- Contract Holder	Female 64	HMO	\$1,869,030 \$1,864,662 \$4,368	2 57	2 79	Skin Burns <ul style="list-style-type: none"> <li>• Burn of third degree of right shoulder, initial encounter</li> <li>• Non-ST elevation (NSTEMI) myocardial infarction</li> <li>• Acute respiratory failure with hypoxia</li> </ul>
Active Employee* ----- Dependent  *FY18 & FY19 HCC	Male 1	PPO	\$1,548,805 \$1,547,997 \$808	1 164	--- 250	Newborn Complications <ul style="list-style-type: none"> <li>• Dyspnea, unspecified</li> <li>• Other chronic respiratory diseases originating in the perinatal period</li> <li>• Other disorders of lung</li> </ul>
Active Employee & Early Retiree ----- Contract Holder	Male 63	PPO	\$1,458,149 \$1,447,811 \$10,338	3 109	--- 194	Neurological Disorders <ul style="list-style-type: none"> <li>• HTN heart &amp; chr kidney disease w HF &amp; stage 1 through 4 CKD or unspec</li> <li>• Other abnormalities of gait &amp; mobility</li> <li>• Unspecified atrial flutter</li> </ul>

## Top 10 Highest Cost Claimants Profile FY19

Status Relationship	Gender Age	Plan	Net Payments Net Medical Net Rx	Admits Days	Visits ER Visits	Episode Summary Group (Highest Cost) Top 3 Dx (Highest Cost)
Active Employee ----- Dependent	Female 0	PPO	\$1,323,223 \$1,301,111 \$22,112	4 119	1 184	Newborn Complications <ul style="list-style-type: none"> <li>Respiratory failure of newborn</li> <li>Acute and chronic respiratory failure with hypoxia</li> <li>Multiple congenital malformations, not elsewhere classified</li> </ul>
Active Employee ----- Contract Holder	Male 54	PPO	\$1,166,022 \$1,166,022 \$0	1 51	--- 43	Cardiovascular Disorders <ul style="list-style-type: none"> <li>ST elevation (STEMI) myocardial infarct involving right coronary artery</li> <li>Acute respiratory failure with hypoxia</li> <li>Cardiogenic shock</li> </ul>
Active Employee ----- Dependent	Male 0	PPO	\$1,153,687 \$1,153,447 \$240	3 227	1 156	Newborn Complications <ul style="list-style-type: none"> <li>Stenosis of larynx</li> <li>Twin liveborn infant, delivered by cesarean</li> <li>Chronic respiratory failure, unspec whether hypoxia or hypercapnia</li> </ul>

# Top 10 Highest Cost Claimants Profile

## FY19

Status Relationship	Gender Age	Plan	Net Payments Net Medical Net Rx	Admits Days	Visits ER Visits	Episode Summary Group (Highest Cost) Top 3 Dx (Highest Cost)
Active Employee _____ Dependent	Male 0	PPO	\$993,010 \$992,917 \$94	7 163	3 222	Chromosomal Abnormalities/Newborn Complications <ul style="list-style-type: none"> <li>• Other deletions of part of a chromosome</li> <li>• Chronic respiratory failure, unspec whether hypoxia or hypercapnia</li> <li>• Acute and chronic respiratory failure with hypoxia</li> </ul>
Active Employee* _____ Dependent  *FY18 & FY19 HCC	Male 11	PPO	\$859,129 \$851,414 \$7,715	11 43	2 186	Leukemia <ul style="list-style-type: none"> <li>• Encounter for antineoplastic chemotherapys</li> <li>• Bloodstream infection due to central venous catheter, initial encounter</li> <li>• Oral mucositis (ulcerative) due to antineoplastic therapy</li> </ul>
Early Retiree* _____ Contract Holder  *FY16-FY19 HCC	Male 62	FSB	\$815,898 \$805,049 \$10,849	5 157	2 230	Cardiomyopathy <ul style="list-style-type: none"> <li>• Acute on chronic diastolic (congestive) heart failure</li> <li>• Acute on chronic systolic and diastolic heart failure</li> <li>• Other hypertrophic cardiomyopathy</li> </ul>
Active Employee _____ Contract Holder	Female 57	HMO	\$804,382 \$799,459 \$4,922	7 129	9 155	Conditions Related to Medical or Surgical Treatment <ul style="list-style-type: none"> <li>• Infection following a procedure, other surgical site, initial encounter</li> <li>• Stenosis of coronary artery stent, initial encounter</li> <li>• ST elevation (STEMI) myocardial infarction involving other sites</li> </ul>

